News & Events
Iconic Therapeutics appoints Julia P. Gregory to Board of Directors
April 6, 2017
According to William Greene, M.D., Chief Executive Officer, “Julia adds to the Board a uniquely rich background in the strategic financing, planning, partnering, and growth of both public and private biotech companies Read more
P2 Science Raises $9.55 Million in Series B Financing Round
March 1, 2017
P2 Science Inc., a venture-backed, biorenewable chemistry company, today announced the close of a $9.55 million Series B financing round. Read more
ViewRay Receives FDA 510(k) Clearance for MRIdian Linac Announces Fourth Quarter and Full Year 2016 Financial Highlights
February 27, 2017
ViewRay, Inc. (Nasdaq: VRAY) announced today that the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the MRIdian Linac system, the company’s next generation linear accelerator-based MRI-guided radiation therapy system. “Our strong performance in 2016, combined with the $26.1 million we raised this January, positions us well for the launch and commercialization of MRIdian Linac,” said Ajay Bansal, chief financial officer of ViewRay. Read more
Iconic Therapeutics to Present Phase 2a Emerge Trial Results at Miami Meeting
February 9, 2017
Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today that the results of its recently completed EMERGE trial. Read more
Chrono Therapeutics Raises $47.6 Million in Series B Financing to Advance its Clinical Platform for Personalized Drug Therapy
September 8, 2016
Chrono Therapeutics, a pioneer in digital drug therapy and recent recipient of the World Economic Forum Technology Pioneer Award, today announced that it has closed a $47.6 million Series B financing. Read more
invendo medical Announces FDA Clearance of the invendoscopy E200 System –Including the First and Only Sterile, Single-use Endoscope For Colonoscopies
September 7, 2016
invendo medical GmbH, a leading developer and distributor of sterile, single-use and robotically-assisted HD endoscopy products in the field of gastroenterology and GI surgery, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the invendoscopy E200 System, which includes the invendoscope SC200 - the first and only sterile, single-use colonoscope. Read more
Iconic Therapeutics Announces Final Close Of Series C Financing With Additional $10 Million Investment
August 9, 2016
Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, today announced the final closing of its Series C financing bringing an additional $10 million into the company and completing the Series C at $48.5 million. Read more
Acutus Medical Completes $75 Million Series C Financing
March 22, 2016
Expands Existing Blue Chip Syndicate with Institutional and Strategic Investors.

Financing Will Support Quest to Transform EP Market by Expanding Clinical Studies and Upcoming European and U.S. Launches of AcQMap. Read more
Dr Ivor Royston agrees to join ViroPro's Board of Directors
December 08, 2015
Viropro, which has signed a non-binding Letter of Intent for the acquisition of NovaRx, a San Diego based pioneer in immuno-oncology, has announced Dr. Ivor Royston has agreed to join its Board of Directors. Read more
Xeraya closes investment into Vittamed Corporation
October 16, 2015
Vittamed ("Company") has become Xeraya's second investment that is structured based on Shariah-compliant principles. The Mudharabah Innovation Fund (managed by Xeraya for the Ministry of Finance) will be a co-investor in Vittamed once the Company has achieved certain Malaysian-centricity milestones.

Vittamed is a neurodiagnostics medical device company that has developed non-invasive ultrasound-based devices to measure intracranial pressure (“ICP”) and monitor cerebral blood flow autoregulation (“CA”), where current standard of care requires invasive methods. The primary focus of the devices is to closely measure and monitor critical care patients suffering from neurological diseases, post-stroke complications or traumatic brain injuries. The Company has received the CE mark for both its devices. Read more
ViewRay® Receives 2015 Frost & Sullivan Technology Innovation Leadership Award
October 13, 2015
ViewRay, a Xeraya portfolio company, has been awarded the 2015 Frost & Sullivan Technology Innovation Leadership Award, a prestigious recognition based on an extensive and independent Frost & Sullivan analysis of the North American Image-Guided Radiation Therapy market, for ViewRay’s MRIdian® system on 13th October 2015. Read more
Sentinext recognized at BioMalaysia 2015
August 18, 2015
Sentinext Therapeutics Sdn Bhd, an investee company of a fund that Xeraya Capital is managing, was awarded the prestigious Bio Innovation of the Year Award 2015 at the BioMalaysia and ASEAN Bioeconomy 2015 Conference held at the Putra World Trade Centre, Kuala Lumpur. Read more
ViewRay completes Alternative Public Offering on US Exchange
July 23, 2015
ViewRay, Inc. (OTCQB: VRAY) announced its successful completion of a reverse merger with ViewRay Technologies, Inc. Read more
Conformis closes IPO on NASDAQ
July 7, 2015
ConforMIS, Inc. (NASDAQ: CFMS), a company in Xeraya's investment portfolio, announced the closing of its initial public offering of 10,350,000 shares of common stock at a public offering price of $15.00 per share. Read more
JJ and Azlin Condolence
April 4, 2015
Sympathy and Condolences to the family members of Semenyih Helicopter Crash Victims. Read more
Xeraya recognised at MVCA award night
March 27, 2015
As a young VC/PE house in Malaysia, Xeraya is honoured to be recognised by the Malaysian Venture Capital Association for its activities throughout 2014. Read more
Xeraya invests into ViewRay Inc.
February 13, 2015
Xeraya Capital has completed funding of a total of USD15 million into ViewRay Incorporated ("ViewRay"), a medical device manufacturer in February 2015. Read more
Press Release on ViroPro
February 2, 2015
PRNewswire, Viropro, Inc. (OTCBB: VPRO) today announced that its Board of Directors completed its strategic review and has begun the implementation of a restructuring designed to restore the company to financial health. Read more
Xeraya in the news: VC Surprise: First close of USD150m Biogreentech Venture Fund
January 12, 2015
Read more
Spruce Capital Partners and Xeraya Capital announced the first close of MLS Capital Fund II, L.P. at $150 million
January 7, 2015
San Francisco and Kuala Lumpur, Malaysia - January 7, 2015 - Spruce Capital Partners and Xeraya Capital today announced the first close of MLS Capital Fund II, L.P. at $150 million. MLS Capital Fund II, the successor to the $162 million Malaysian Life Sciences Capital Fund, is co-managed by Spruce Capital Partners and Xeraya Capital, which will invest the funds in a diversified portfolio of biogreentech companies at all stages of development. Read more
Passing away of Rashidan Shah, Xeraya's Investment Director
October 27, 2014
It is with profound sadness that Xeraya announces the sudden passing away of Xeraya's Investment Director, Rashidan, a cherished colleague and friend, on the Monday morning of 27th October 2014. Read more
PrIME Biologics Announces SGD16M in Equity Funding Led by Xeraya Capital
October 7, 2014
PrIME Biologics Announces SGD16M in Equity Funding Led by Xeraya Capital. Investment will help establish first human blood fractionation plant in South East Asia. Read more
Stryker completed asset purchase of SBI
October 6, 2014
Stryker (NYSE:SYK) said it closed the acquisition of Small Bone Innovations by adding SBi's operations in Europe and Asia. In June, Kalamazoo, Mich.-based Stryker agreed to pay up to $375 million for SBi, which was founded in 2004 to sell products and technologies to treat trauma and diseases in the small bones and joints. SBi has facilities in Morrisville, Pa., Péronnas, France, Donaueschingen, Germany, and Kuala Lumpur. Read more
Key Appointment on Invendo Board
July 30, 2014
NEW YORK and KISSING, Germany, July 30, 2014 - invendo medical GmbH, manufacturer and distributor of a single use and computer-assisted ("robotic") colonoscopy system, today announced the appointment of Nachum (Homi) Shamir, a worldwide recognized medical device executive, as a new member of its supervisory board. Read more
Xeraya in the news: Xeraya wins Deal of the Month from Acquisition International for the investment into Invendo Medical
July 2014
Read more
Invendo medical Closes Euro 20M Equity Capital Funding Led by Xeraya Capital
March 20, 2014
KISSING, Germany and GARDEN CITY, New York, March 20, 2014 (ANTARA/PRNewswire) - invendo medical, manufacturer and distributor of a single-use and computer-assisted colonoscopy system, today announced the closing of a euro 20.3 million ($ 28 million) financing round led by new investor Xeraya Capital Sdn Bhd ("Xeraya Capital"), which invested via an affiliated company. Read more